NK and MSCs Crosstalk: The Sense of Immunomodulation and Their Sensitivity

Stem Cell Reviews and Reports

Volumn 9, Issue 2, 2013, Pages 184-189

  Casado, Javier G ^a   Tarazona, R ^b   Sanchez Margallo, F M ^a  

^a JESÚS USÓN MINIMALLY INVASIVE SURGERY CENTRE   (Spain)

^b UNIVERSITY OF EXTREMADURA   (Spain)

Author keywords

Immunomodulation; Innate Response; Mesenchymal stem cells; NK cell mediated lysis; NK cells

Indexed keywords

EID: 84875596225     PISSN: 15508943     EISSN: 15586804     Source Type: Journal    
DOI: 10.1007/s12015-013-9430-y     Document Type: Review

References (45)

1. Chen, X., Armstrong, M. A., & Li, G. (2006). Mesenchymal stem cells in immunoregulation. Immunology and Cell Biology, 84(5), 413-421.
2. Stagg, J. (2007). Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens, 69(1), 1-9.
3. Shi, Y., Su, J., Roberts, A. I., et al. (2012). How mesenchymal stem cells interact with tissue immune responses. Trends in Immunology, 33(3), 136-143.
4. English, K., & Mahon, B. P. (2011). Allogeneic mesenchymal stem cells: agents of immune modulation. Journal of Cellular Biochemistry, 112(8), 1963-1968.
5. Zhao, S., Wehner, R., Bornhauser, M., et al. (2010). Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells and Development, 19(5), 607-614.
6. Gebler, A., Zabel, O., & Seliger, B. (2011). The immunomodulatory capacity of mesenchymal stem cells. Trends in Molecular Medicine, 18(2), 128-134.
7. Rasmusson, I., Uhlin, M., Le, B. K., & Levitsky, V. (2007). Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. Journal of Leukocyte Biology, 82(4), 887-893.
8. Chen, L., Zhang, W., Yue, H., et al. (2007). Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells and Development, 16(5), 719-731.
9. Ramasamy, R., Fazekasova, H., Lam, E. W., et al. (2007). Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation, 83(1), 71-76.
10. Prigione, I., Benvenuto, F., Bocca, P., et al. (2009). Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells, 27(3), 693-702.
11. Chen, L., Tredget, E. E., Wu, P. Y., & Wu, Y. (2008). Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One, 3(4), e1886.
12. Krasnodembskaya, A., Samarani, G., Song, Y., et al. (2012). Human mesenchymal stem cells reduce mortality and bacteremia in gram negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. American Journal of Physiology. Lung Cellular and Molecular Physiology, 302(10), L1003-L1013.
13. Tu, Z., Li, Q., Bu, H., & Lin, F. (2010). Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells and Development, 19(11), 1803-1809.
14. Yagi, H., Soto-Gutierrez, A., Parekkadan, B., et al. (2010). Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplantation, 19(6), 667-679.
15. Deak, E., Seifried, E., & Henschler, R. (2010). Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications. International Reviews of Immunology, 29(5), 514-529.
16. Rasmusson, I., Ringden, O., Sundberg, B., & Le, B. K. (2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation, 76(8), 1208-1213.
17. Gotherstrom, C., Lundqvist, A., Duprez, I. R., et al. (2011). Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy, 13(3), 269-278.
18. Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N., & Papamichail, M. (2006). Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells, 24(1), 74-85.
19. Spaggiari, G. M., Capobianco, A., Becchetti, S., Mingari, M. C., & Moretta, L. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 107(4), 1484-1490.
20. Poggi, A., Prevosto, C., Massaro, A. M., et al. (2005). Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. Journal of Immunology, 175(10), 6352-6360.
21. Karre, K. (2008). Natural killer cell recognition of missing self. Nature Immunology, 9(5), 477-480.
22. DelaRosa, O., Sanchez-Correa, B., Morgado, S., et al. (2011). Human adipose-derived stem cells impair NK cell function and exhibit low susceptibility to NK-mediated lysis. Stem Cells and Development, 21(8), 1333-1343.
23. El, H. N., Moore, R., Heathcote, D., et al. (2011). The novel role of SERPINB9 in cytotoxic protection of human mesenchymal stem cells. Journal of Immunology, 187(5), 2252-2260.
24. Hoogduijn, M. J., Roemeling-van, R. M., Korevaar, S. S., et al. (2011). Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies. Human Gene Therapy, 22(12), 1587-1591.
25. Bartholomew, A., Sturgeon, C., Siatskas, M., et al. (2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Experimental Hematology, 30(1), 42-48.
26. Noort, W. A., Kruisselbrink, A. B., in't Anker PS, et al. (2002). Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Experimental Hematology, 30(8), 870-878.
27. Barry, F. P. (2003). Biology and clinical applications of mesenchymal stem cells. Birth Defects Research. Part C, Embryo Today, 69(3), 250-256.
28. Jorgensen, C., Djouad, F., Apparailly, F., & Noel, D. (2003). Engineering mesenchymal stem cells for immunotherapy. Gene Therapy, 10(10), 928-931.
29. Le, B. K. (2003). Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy, 5(6), 485-489.
30. Ghannam, S., Pene, J., Torcy-Moquet, G., Jorgensen, C., & Yssel, H. (2010). Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. Journal of Immunology, 185(1), 302-312.
31. Zheng, Z. H., Li, X. Y., Ding, J., Jia, J. F., & Zhu, P. (2008). Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology (Oxford, England), 47(1), 22-30.
32. Gonzalez-Rey, E., Gonzalez, M. A., Varela, N., et al. (2010). Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Annals of the Rheumatic Diseases, 69(1), 241-248.
33. Gonzalez-Rey, E., Anderson, P., Gonzalez, M. A., et al. (2009). Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut, 58(7), 929-939.
34. Rasmusson, I., Le, B. K., Sundberg, B., & Ringden, O. (2007). Mesenchymal stem cells stimulate antibody secretion in human B cells. Scandinavian Journal of Immunology, 65(4), 336-343.
35. Svobodova, E., Krulova, M., Zajicova, A., et al. (2012). The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells and Development, 21(6), 901-910.
36. Spaggiari, G. M., Abdelrazik, H., Becchetti, F., & Moretta, L. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood, 113(26), 6576-6583.
37. Aggarwal, S., & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105(4), 1815-1822.
38. Krampera, M., Cosmi, L., Angeli, R., et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24(2), 386-398.
39. Yakar, I., Melamed, R., Shakhar, G., et al. (2003). Prostaglandin e(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Annals of Surgical Oncology, 10(4), 469-479.
40. Chen, Y., Perussia, B., & Campbell, K. S. (2007). Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor. Journal of Immunology, 179(5), 2766-2773.
41. Torres, D., Paget, C., Fontaine, J., et al. (2008). Prostaglandin D2 inhibits the production of IFN-gamma by invariant NK T cells: consequences in the control of B16 melanoma. Journal of Immunology, 180(2), 783-792.
42. Giuliani, M., Oudrhiri, N., Noman, Z. M., et al. (2011). Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood, 118(12), 3254-3262.
43. Ryan, J. M., Barry, F., Murphy, J. M., & Mahon, B. P. (2007). Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clinical and Experimental Immunology, 149(2), 353-363.
44. Ren, G., Zhang, L., Zhao, X., et al. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2(2), 141-150.
45. Almeida, C. R., Vasconcelos, D. P., Goncalves, R. M., & Barbosa, M. A. (2012). Enhanced mesenchymal stromal cell recruitment via natural killer cells by incorporation of inflammatory signals in biomaterials. Journal of the Royal Society, Interface, 9(67), 261-271.